1.
Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Grigoriy Rekhtman, Zvenyslava Masliak, Pawel Robak, Dixie-Lee Esseltine, Huaibao Feng, William Deraedt, Helgi van de Velde, Bertrand Arnulf. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica 2015;100(5):e207-e210; https://doi.org/10.3324/haematol.2014.118182.